Introduction {#tca12343-sec-0005}
============

Lung cancer is the leading cause of death from cancer.[1](#tca12343-bib-0001){ref-type="ref"} Non‐small‐cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. Unfortunately, few treatment options are available for patients with advanced or metastatic NSCLC.

In 2004, two pivotal studies proved that the somatic mutation in epidermal growth factor receptor (EGFR) can be detected in most patients with NSCLC, and was strongly relevant to high responsiveness to EGFR‐tyrosine kinase inhibitors (TKIs).[2](#tca12343-bib-0002){ref-type="ref"}, [3](#tca12343-bib-0003){ref-type="ref"} Small molecule EGFR‐TKIs were the first target drugs to be applied and widely used as a clinical treatment strategy for NSCLC. The two classical EGFR mutations are deletion of exon 19 (19del) and a single point mutation of L858R in exon 21 (21 L858R).[4](#tca12343-bib-0004){ref-type="ref"} Although patients with an EGFR mutation usually benefit more from EGFR‐TKI treatment than those with wild type, different subtypes of EGFR mutations respond to EGFR‐TKI treatment.[5](#tca12343-bib-0005){ref-type="ref"}

Several studies have reported that advanced NSCLC patients with exon 19del accepting EGFR‐TKI therapy had a relatively longer progression‐free survival (PFS) and/or overall survival (OS) than those with an exon 21 L858R mutation.[6](#tca12343-bib-0006){ref-type="ref"}, [7](#tca12343-bib-0007){ref-type="ref"}, [8](#tca12343-bib-0008){ref-type="ref"}, [9](#tca12343-bib-0009){ref-type="ref"} However, this issue is controversial at present, as several studies have also shown no significant difference in EGFR‐TKI efficacy between the two subtypes of mutations.[7](#tca12343-bib-0007){ref-type="ref"}, [10](#tca12343-bib-0010){ref-type="ref"}

Therefore, we performed this meta‐analysis to evaluate whether there is a correlation between the theraputic efficacy of EGFR‐TKIs and these two classical subtypes of EGFR mutations in advanced NSCLC. We also sought to accurately predict clinical prognosis in the patients who accepted EGFR‐TKI therapy.

Methods {#tca12343-sec-0006}
=======

Literature search {#tca12343-sec-0007}
-----------------

Two investigators independently searched eligible trials, and discrepancies were resolved by discussion between them. All relevant articles were identified with an English language search of PubMed and Web of Science using a combination of the keywords: "EGFR," "EGF receptor," "epidermal growth factor receptor," "tyrosine kinase inhibitors" or "TKI," and "non small cell lung cancer" or "NSCLC" from 2004--2015. The last search was performed on May 30, 2015, and studies were conducted using Prefered Reporting Items For Systematic Reviews and Meta‐analyses (PRISMA) standards.[11](#tca12343-bib-0011){ref-type="ref"}

Study criteria {#tca12343-sec-0008}
--------------

Studies were considered eligible if they met the following criteria: (i) prospective or retrospective clinical studies designed to investigate advanced or metastatic NSCLC (stage III--IV) with monotherapy of EGFR‐TKIs (gefitinib or erlotinib), first line or otherwise; (ii) patients harbored EGFR mutations (exon 19 del or 21 L858R); (iii) EGFR mutation was identified by tumor tissue samples rather than peripheral blood; (iv) all included patients were evaluated by treatment response, PFS, and OS (defined by Response Evaluation Criteria in Solid Tumors; complete and partial response were categorized to response, stable, or progressive); and (v) for the same study, only the most recent publication results were included.

Quality assessment and data extraction {#tca12343-sec-0009}
--------------------------------------

Two investigators independently assessed the quality of studies using the Newcastle Ottawa Quality Assessment Scale, which was composed of eight items to assess patient selection, study comparability and outcome; the use of controversial literature was resolved by discussion with the third investigator in order to reach accordance.[12](#tca12343-bib-0012){ref-type="ref"}

The following data were extracted from the included studies: (i) general information (lead author\'s name, publication time, and study type); (ii) features (treatment, treatment line, and sample size of EGFR mutation subtypes); and (iii) evaluation indexes (ORR, PFS, 1‐year PFS, OS and 2‐year OS; if the data couldn\'t be obtained directly, we calculated from the survival curve).

Survival curve data were preferably provided as survival data for a given period, for example, a one, two, three, or five‐year survival number/ratio. However, survival data needed to be directly extracted from the Kaplan‐Meier curve for two prospective and four retrospective studies. In this method, the x‐axis of the Kaplan--Meier curve was divided into given intervals equaling years of follow‐up, then a researcher read the survival ratio at the each time point using the GetData Graph Digitizer 2.2 (Informer Technologies Inc., Madrid, Spain).[13](#tca12343-bib-0013){ref-type="ref"} This method was considered weak but necessary, because some of the earlier studies did not provide survival ratio information at each time point. This weakness is shared by our analysis and some previously published meta‐analyses.

Statistical analysis {#tca12343-sec-0010}
--------------------

The meta‐analysis of the odds radio (OR) for objective responses and the one‐year PFS and two‐year OS rates were calculated using RevMan (Review Manager Version 5.3 for Windows, Cochrane Collaboration, Oxford, UK) and a pooled relative risk was calculated with 95% confidence intervals (CIs).

To undertake a random effects meta‐analysis, the standard errors of the study‐specific estimates are adjusted to incorporate a measure of the extent of variation or heterogeneity among the treatment effects observed in different studies. Statistical heterogeneity was evaluated using *I* ^2^ statistics and *X* ^2^‐based tests, and a *P* value of \< 0.05 was considered statistically significant.

In the *I* ^2^ test, *I* ^2^ = 0% indicated no heterogeneity; *I* ^2^ (0%, 40%) indicated low heterogeneity; *I* ^2^ (40%, 60%) indicated moderate heterogeneity; *I* ^2^ (50%, 90%) indicated high heterogeneity; *I* ^2^ (75%, 100%) indicated maximum heterogeneity; and the X^2^ distribution test used a rejection region equal to 0.1.[14](#tca12343-bib-0014){ref-type="ref"}

A funnel plot test was used to evaluate the existence of publication bias.

Results {#tca12343-sec-0011}
=======

As shown in Figure [1](#tca12343-fig-0001){ref-type="fig"}, we researched 706 studies from PubMed and 365 additional studies from Web of Science. After a screening process using PRISMA standards, we included seven prospective studies (508 patients with exon 19del and 354 with exon 21 L858R mutations) into a comprehensive meta‐analysis and included six retrospective studies for a supplementary meta‐analysis. The characteristics of the eligible studies are summarized in Tables [1](#tca12343-tbl-0001){ref-type="table-wrap"} and [2](#tca12343-tbl-0002){ref-type="table-wrap"}.^6,7,9,10,^ [15](#tca12343-bib-0015){ref-type="ref"}, [16](#tca12343-bib-0016){ref-type="ref"}, [17](#tca12343-bib-0017){ref-type="ref"}, [18](#tca12343-bib-0018){ref-type="ref"}, [19](#tca12343-bib-0019){ref-type="ref"}, [20](#tca12343-bib-0020){ref-type="ref"}, [21](#tca12343-bib-0021){ref-type="ref"}

![Flow diagram of patients included in the meta‐analysis. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.](TCA-7-406-g001){#tca12343-fig-0001}

###### 

Characteristics of included prospective studies for meta‐analysis

  Lead author (year)   Phase       Treatment line   Therapeutic regimen of TKI   Type of EGFR mutation   Sample size (TKI treatment)   ORR (%)   PFS (months) (95% CI)   OS (months) (95% CI)   Score
  -------------------- ----------- ---------------- ---------------------------- ----------------------- ----------------------------- --------- ----------------------- ---------------------- -------
  Sugio (2008)         Pro (II)    1                Gefitinib 250 mg/d, po       19del                   7                             71.4      --                      --                     6
                                                                                 21 L858R                10                            60        --                      --                     
  Kim (2011)           Pro (II)    Mix              Gefitinib 250 mg/d, po       19del                   29                            62.1      16.5 (12.5--19.3)       NA (24.9‐NA)           7
                                                                                 21 L858R                15                            33.3      6.9 (3.6--13.3)         16.2 (11.2--27.3)      
  Iuchi (2013)         Pro (II)    1                Gefitinib 250 mg/d, po       19del                   23                            100       17.5 (13.9‐NA)          30.3                   7
                                                    or Erlotinib 150 mg/d, po    21 L858R                15                            80        10.2 (7.2‐NA)           19.8                   
  Yamada (2013)        Pro (II)    2,3              Erlotinib 150 mg/d, po       19del                   19                            47.4      8.0 (3.8--10.4)         --                     9
                                                                                 21 L858R                7                             71.4      11.6 (8.3--11.6)        --                     
  Goto (2013)          Pro (II)    Mix              Erlotinib 150 mg/d, po       19del                   50                            84        12.5 (10.3--16.6)       --                     7
                                                                                 21 L858R                51                            76        11.0 (6.9--15.2)        --                     
  Mitsudomi (2010)     Pro (III)   1                Gefitinib 250 mg/d, po       19del                   50                            --        9.0 (6.7--13.0)         --                     8
                                                                                 21 L858R                36                            --        9.6 (8.0--13.8)         --                     
  Maemondo (2010)      Pro, RCT    1                Gefitinib 250 mg/d, po       19del                   58                            82.8      11.5                    --                     9
                                                                                 21 L858R                49                            67.3      10.8                    --                     

19del, exon 19 deletion; CI, confidence interval; EGFR, epidermal growth factor receptor; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival; po, orally; Pro, prospective study; RCT, randomized controlled trial; TKI, tyrosine kinase inhibitor.

2016 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd

###### 

Characteristics of included retrospective studies for complementary meta analysis

  Lead author (year)   Treat line   Therapeutic regimen of TKI   Type of EGFR mutation   Sample size (TKI treatment)   ORR (%)   PFS (months) (95% CI)   OS (months) (95% CI)   Score
  -------------------- ------------ ---------------------------- ----------------------- ----------------------------- --------- ----------------------- ---------------------- -------
  Won (2011)           Mix          Gefitinib 250 mg/d, po       19del                   61                            63.9      9.3 (7.5 to 11.1)       17.7 (12.3 to 23.1)    7
                                    or Erlotinib 150 mg/d, po    21 L858R                26                            61.5      6.9 (4.1 to 9.7)        20.5 (3.8--37.2)       
  Lee (2013)           1            Gefitinib 250 mg/d, po       19del                   64                            87.5      12.8                    24.6                   9
                                    or Erlotinib 150 mg/d, po    21 L858R                80                            75.3      11.4                    21                     
  Jackman (2006)       Mix          Gefitinib 250 mg/d, po       19del                   22                            73        24                      38                     6
                                    or Erlotinib 150 mg/d, po    21 L858R                10                            50        10                      17                     
  Yoshida (2007)       Mix          Gefitinib 250 mg/d, po       19del                   8                             87.5      7.8 (7.6‐NA)            --                     8
                                                                 21 L858R                13                            92.3      6 (2.6 to 7.7)          --                     
  Igawa (2014)         Mix          Gefitinib 250 mg/d, po       19del                   68                            61.8      11.3 (8.0 to 14.6)      32.2 (22.0 to 42.4)    8
                                                                 21 L858R                56                            58.9      9 (6.7 to 11.3)         22.7 (9.4 to 36.0)     
  Takano (2006)        Mix          Gefitinib 250 mg/d, po       19del                   49                            86        10.5                    22                     7
                                                                 21 L858R                36                            67        7.4                     12                     

19del, exon 19 deletion; CI, confidence interval; EGFR, epidermal growth factor receptor; NA, not available; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival; po, orally; Pro, prospective study; RCT, randomized controlled trial; TKI, tyrosine kinase inhibitor.

2016 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd

Response rate {#tca12343-sec-0012}
-------------

As Figure [2](#tca12343-fig-0002){ref-type="fig"} shows, ORR data was available in six prospective trials, including five phase II and one randomized controlled trial (*n* = 333). Heterogeneity testing revealed a fixed effects model without significant heterogeneity (*I* ^2^ =10 %; *P* = 0.35). The ORR of the 19del group was significantly higher than the 21 L858R group (78.0% \[145/186\] vs. 68.0% \[100/147\], OR 1.98, 95% CI 1.18--3.33; *P* = 0.01; Fig [2](#tca12343-fig-0002){ref-type="fig"}).

![Forest plot of overall response rates of exon 19 deletion and 21 L858R mutation in prospective and retrospective studies. CI, confidence interval; M‐H, Mantel‐Haenszel.](TCA-7-406-g003){#tca12343-fig-0002}

Furthermore, a complementary meta‐analysis was performed on six retrospective studies (*n* = 493; Fig [2](#tca12343-fig-0002){ref-type="fig"}). The estimated proportion of the ORR in heterogeneity (*I* ^2^) was 0%, (*P* = 0.49). Patients with an exon 19del had a significantly higher ORR than patients with an exon 21 L858R mutation (74.3% \[202/272\] vs. 67.9% \[150/221\], OR 1.62, 95% CI 1.07--2.45; *P* = 0.02). The pooling of data from prospective and retrospective studies (*n* = 826) demonstrated a statistically significant ORR in patients with an exon 19del compared with those with an exon 21 L858R mutation (OR 1.75, 95% CI 1.27--2.42; *P* = 0.0007).

One‐year progression‐free survival rate {#tca12343-sec-0013}
---------------------------------------

Six prospective trials (*n* = 401) included one‐year PFS data. The median PFS was 8.0--16.5 months in the 19del and 6.9--11.6 months in the 21 L858R group (Table [1](#tca12343-tbl-0001){ref-type="table-wrap"}). The estimated proportion of heterogeneity (*I* ^2^) between these six studies was 48% (*P* = 0.09) for one‐year PFS of the 19del group versus the 21 L858R group. As Figure [3](#tca12343-fig-0003){ref-type="fig"} demonstrates, patients with 19del had higher one‐year PFS than patients with the 21 L858R mutation (44.1% \[101/229\] vs. 35.4% \[61/172\], OR 1.44, 95% CI 0.96--2.18; *P* = 0.08).

![Forest plot of one‐year progression‐free survival rates of exon 19 deletion and 21 L858R mutation in prospective studies. CI, confidence interval; M‐H, Mantel‐Haenszel.](TCA-7-406-g008){#tca12343-fig-0003}

We conducted a supplementary meta‐analysis using five retrospective studies, as shown in Figure [4](#tca12343-fig-0004){ref-type="fig"}. Heterogeneity testing revealed that there was light heterogeneity (*I* ^2^ = 30%; *P* = 0.22), and patients with a 19del mutation had a significantly higher one‐year PFS rate than patients with an exon 21 L858R mutation (48.0% \[118/264\] vs. 32.2% \[67/208\], OR 1.73, 95% CI 1.17--2.56; *P* = 0.006).

![Forest plot of one‐year progression‐free survival rates of exon 19 deletion and 21 L858R mutation in retrospective studies. CI, confidence interval; M‐H, Mantel‐Haenszel.](TCA-7-406-g009){#tca12343-fig-0004}

Two‐year overall survival rate {#tca12343-sec-0014}
------------------------------

The two‐year OS rate was available in two prospective trials (*n* = 82), both of which demonstrated that patients with a 19del mutation had a longer OS (24.9--30.3 months) than those with 21 L858R mutations (16.2--22.1 months; Table [1](#tca12343-tbl-0001){ref-type="table-wrap"}).[16](#tca12343-bib-0016){ref-type="ref"}, [17](#tca12343-bib-0017){ref-type="ref"} The *I* ^2^ statistic in the fixed effects model did not show significant heterogeneity (*I* ^2^ = 0 %; *P* = 0.52), and pooling analysis revealed that patients with an exon 19del mutation had a statistically significantly higher two‐year OS rate than patients with an exon 21 L858R mutation (55.8% \[29/52\] vs. 20% \[6/30\], OR 5.27, 95% CI 1.76--15.71; *P* = 0.003), as shown in Figure [5](#tca12343-fig-0005){ref-type="fig"}.

![Forest plot of two‐year overall survival rates of exon 19 deletion and 21 L858R mutation in prospective studies. CI, confidence interval; M‐H, Mantel‐Haenszel.](TCA-7-406-g006){#tca12343-fig-0005}

Assessment of heterogeneity and publication bias {#tca12343-sec-0015}
------------------------------------------------

There was light statistical heterogeneity among the 13 trials and no publication bias for outcome measures, with asymmetrical appearance on funnel plot analysis of the relative ORR (Fig [6](#tca12343-fig-0006){ref-type="fig"}).

![Funnel plot of the relative overall response rates. ![](TCA-7-406-g007.jpg "image"), Prospective study; ![](TCA-7-406-g004.jpg "image"), Retrospective study. RR, relative risk; SE, standard error.](TCA-7-406-g005){#tca12343-fig-0006}

Discussion {#tca12343-sec-0016}
==========

In 2014, two meta‐analyses of the correlation between EGFR‐TKIs and EGFR sensitive mutation subtypes in advanced or metastatic NSCLC were published. However, the two studies did not perfectly resolve the issue. Zhang *et al*. compared patients with an exon 19del who accepted EGFR‐TKI treatment with those with a 21 L858R mutation.[24](#tca12343-bib-0024){ref-type="ref"} Their results revealed significantly superior ORR, PFS, and OS in the 19del mutation group compared with the 21 L858R mutation group. However, their meta‐analysis lacked data, which led to incomplete results in the prospective subgroup meta‐analysis and indicated that PFS and OS rates in the 19del group had no significance. Wang *et al*.\'s meta‐analysis was based on 22 studies published mainly during 2006--2011; as further studies have been published and renewed in the last three years, the quality of our data is superior. Their study focused on patients who received first‐line EGFR‐TKIs and demonstrated that patients with an exon 19del mutation have a longer PFS compared with those with an L858R mutation.[25](#tca12343-bib-0025){ref-type="ref"} They extracted hazard ratios (HR) for the PFS rate of TKIs/chemotherapy in 19del and 21 L858R subgroups and calculated the specific HR value to speculate the ratio of PFS, which means that a confounding bias may exist in their meta‐analysis. In our study, we performed a more comprehensive meta‐analysis, including evidence from both prospective and retrospective studies. In order to obtain an objective and accurately evaluated result and to assess the therapeutic effects of TKIs, we selected three indicators: an ORR indicated a short‐term effect, one‐year PFS a middle‐term effect, and two‐year OS a long‐term effect.

In our study, patients with an exon 19del had a significantly higher ORR after EGFR‐TKI therapy than patients with an exon 21 L858R mutation in both prospective (OR 1.98, 95% CI 1.18--3.33; *P* = 0.01) and retrospective subgroup analyses (OR 1.62, 95% CI 1.07--2.45; *P* = 0.02). Correspondingly, pooling the statistical results indicated a significant difference between the mutations (OR 1.75, 95% CI 1.27--2.42; *P* = 0.0007), suggesting that in advanced NSCLC, patients with an exon 19del usually experienced superior short‐term efficacy from EGFR‐TKIs than those with an exon 21 L858R mutation. Our meta‐analysis of the prospective subgroup indicated that the exon 19del group had a higher one‐year PFS than the 21 L858R mutation group, but the difference between them had no statistical significance (OR 1.44, 95% CI 0.96--2.18; *P* = 0.08). However, in retrospective subgroup meta‐analysis, the exon 19del group had a significantly higher one‐year PFS rate (OR 1.73, 95% CI 1.17--2.56; *P* = 0.006). Analyzing these six prospective studies individually, two studies demonstrated that the 21 L858R group had a longer PFS compared with the 19del group.[18](#tca12343-bib-0018){ref-type="ref"}, [20](#tca12343-bib-0020){ref-type="ref"} Thus, once the restrospective subgroup meta‐analysis was combined with the prospective meta‐analysis, it was clear that the results for the 19del group had been affected by the data from the two studies indicating that the 21 L858R group had a longer PFS. One of these, a phase II study of erlotinib, found PFS rates of the 19del (*n* = 19) and 21 L858R groups (*n* = 7) of 8.0 and 11.6 months, respectively (*P* = 0.1084), with no significant difference.[18](#tca12343-bib-0018){ref-type="ref"} This study had limited sufficient data, which might affect our result. The second study, WJTOG3405, was a phase III trial, in which the PFS rates of the 19del (*n* = 50) and 21 L858R groups (*n* = 36) were 9.0 versus 9.6 months, a difference with no statistical significance (*P* = 0.681).[20](#tca12343-bib-0020){ref-type="ref"} We consider that the WJTOG3405 result is not representative of phase III studies, as other phase III trials (OPTIMAL, IPASS, EURTAC, LUX‐Lung 3, and LUX‐Lung 6) have demonstrated that the HR of TKI/chemotherapy for PFS in the 19del group was lower than in 21 L858R group, suggesting that the PFS in patients with the 19del mutation was longer; however, we excluded these studies as raw data was not available.[26](#tca12343-bib-0026){ref-type="ref"} ^--^ [30](#tca12343-bib-0030){ref-type="ref"} Considering these limitations, we reanalyzed the difference in one‐year PFS between the 19del and 21 L858R subgroups, leaving out the results of these two studies. Patients with 19del had higher one‐year PFS rates than patients with the 21 L858R mutation (50% \[80/160\] vs. 38.0% \[49/129\], OR 1.59, 95% CI 1.00--2.55; *P* = 0.05; Fig [7](#tca12343-fig-0007){ref-type="fig"}).

![Forest plot of one‐year progression‐free survival rates of exon 19 deletion and 21 L858R mutation in prospective studies reanalyzed. CI, confidence interval; M‐H, Mantel‐Haenszel.](TCA-7-406-g002){#tca12343-fig-0007}

Although the evidence‐based lever of retrospective studies is relatively low, some retrospective studies have shown persuasive results. For example, a retrospective study published in the *New England Journal of Medicine* also revealed that patients with a 19del mutation experienced a longer PFS and OS than those with the 21 L858R, and the difference was statistically significant.[31](#tca12343-bib-0031){ref-type="ref"} Therefore, we arranged a retrospective subgroup meta‐analysis as a supplement to enlarge the sample size, which demonstrated a significantly higher one‐year PFS rate in the 19del group than the 21 L858R group.

In our meta‐analysis, the two‐year OS rate of the 19del group was significantly superior to the 21 L858R group (OR 5.27, 95% CI 1.76--15.71; *P* = 0.003), consistent with previous reports.[8](#tca12343-bib-0008){ref-type="ref"}, [10](#tca12343-bib-0010){ref-type="ref"}, [31](#tca12343-bib-0031){ref-type="ref"} In addition, the ORR, one‐year PFS, and two‐year OS rates suggest that patients harboring an exon 19del might display a higher sensitivity to EGFR‐TKI therapy than those harboring an exon 21 L858R point mutation; the difference in efficacy will become increasingly obvious over time and finally affect their survival.

However, advanced NSCLC patients with an exon 19del who did not accept EGFR‐TKI treatment failed to acquire such a superior prognosis to those with the 21 L858R mutation. The NEJ002 study showed that patients with an exon 19del had a higher ORR with gefitinib than patients with an L858R mutation (82.8% vs. 67.3%) and patients who were treated by carboplatin plus paclitaxel alone, who had a low ORR (30.5% vs. 30.3%).[32](#tca12343-bib-0032){ref-type="ref"} Shigematsu *et al*. reported that in NSCLC patients with these two subtypes of EGFR mutation who accepted surgical resection but not EGFR‐TKI, those with L858R had a relatively prolonged survival compared with patients with an exon 19del (*P* = 0.05).[33](#tca12343-bib-0033){ref-type="ref"}

These results suggest that the different efficacies of EGFR‐TKI in patients with these two subtypes of sensitive mutation are likely related to a molecular biology mechanism: the EGFR exon 19del eliminates a leucine‐arginine‐glutamate‐alanine motif in the tyrosine kinase domain of EGFR, while an exon 21 L858R mutation performs a thymine‐to‐guanine transversion that results in arginine for leucine substitution at amino acid 858.[34](#tca12343-bib-0034){ref-type="ref"} Although no study has compared affinity when TKIs are combined with the exon 19del or 21 L858R mutation, Yun *et al*. reported that different mutations of EGFR resulted in different affinities for gefitinib and other TKIs.[35](#tca12343-bib-0035){ref-type="ref"} This suggests that the exon 19del of EGFR leads to a special structural change, which combines with TKIs faster than in the 21 L858R mutation. Zhu *et al*. obtained two stable cell lines expressing these two subtype mutations by transfection, and found that gefitinib inhibited the phosphorylation of EGFR, protein kinase B, and extracellular‐signal‐related‐kinase significantly greater in HEK293/19del cells than in HEK293/L858R cells, and the production of G1 arrest in exon 19del cells was higher than in L858R cells.[36](#tca12343-bib-0036){ref-type="ref"} Banno *et al*. used a methyl thiazolyl tetrazolium assay to examine sensitivities to AG1478 (a reversible EGFR‐TKI) and afatinib in NSCLC cell lines harboring EGFR exon 19del (PC‐9 and HCC827 cell lines) and 21 L858R mutations (11_18 cell line). The inhibitory concentration 50 of both AG1478 and afatinib of the PC‐9 and HCC827 cell lines were lower than that of the 11_18 cell line.[37](#tca12343-bib-0037){ref-type="ref"} These two studies suggest that cells harboring the exon 19del are more sensitive to EGFR‐TKIs than those with the 21 L858R mutation. Nevertheless, the mechanisms are still not well understood and require further examination.

Our meta‐analysis has several limitations. First, few studies have focused on the the prognostic value of different EGFR mutation types as to the efficacy of EGFR‐TKI, and some data came from subgroups, which might lead to incomplete results. Second, our meta‐analysis included seven retrospective studies. Although the evidence‐based lever of retrospective studies is low, we only employed it as a supplementary analysis, and the results supported those determined by prospective study analysis. Third, despite some heterogeneity between the studies, this was light (0--35%) and had no influence on the outcome of meta‐analysis.

Conclusion {#tca12343-sec-0017}
==========

For advanced NSCLC patients, exon 19del might provide superior ORR, PFS, and OS from EGFR‐TKI treatment compared with those with exon 21 L858R mutations. Therefore, it should be considered an essential factor in clinial EGFR‐TKI therapy.
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